Equity Research Specialty Chemicals

Should You Buy Aemetis, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 2/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Aemetis, Inc. (AMTX) scores 4.5/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $1.87, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 2 of 2 CirclFi valuation models project upside for Aemetis, Inc. (AMTX) at $1.87 — the model consensus leans bullish, with a Quality Score of 4.5/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 2 of 2 models see upside — majority bullish
  • Quality Score: 4.5/10 — Weak — below-average fundamentals
  • Value Trap Risk: 26/100 — Low — manageable risk
  • Fair Value Range: $1.90 – $2.96 (56% spread)

Bullish Models

2 / 2

Bearish Models

0 / 2

Quality Score

4.5 /10

Weak — below-average fundamentals

Value Trap Risk

26 /100
Low

Low — manageable risk

Model Consensus

2 /13
Active Models

Avg. confidence: 41%

What Is the Investment Case for Aemetis, Inc. (AMTX) in 2026?

What Is the Bull Case vs the Bear Case for Aemetis, Inc. (AMTX)?

Bull case versus bear case for Aemetis, Inc. (AMTX) at $1.87, derived from 2 active CirclFi valuation models on 2026-08-27.
Bull case — $2.96 target (+58.1%) Bear case
According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $1.87 and the median fair value of $2.43 implies +29.9% upside potential. No active model flags significant downside for AMTX. The low Value Trap score paints a constructive picture.
According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $2.96 (+58.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
Industry tailwind: automation and productivity gains could provide meaningful support for Aemetis, Inc.'s revenue and margin trajectory in the Specialty Chemicals space.

How Does AMTX Compare to Its Specialty Chemicals Peers?

CLMT Calumet, Inc.
4.9
FEAM 5E Advanced Material
4.4
LOOP Loop Industries, Inc
5.3
KBLB Kraig Biocraft Labor
4.4
CITR CitroTech Inc.
5.3
FEAV 5E Advanced Material
4.2
NEU NewMarket Corporatio
8.8
HDSN Hudson Technologies,
7.6

Valuation data pages: CLMT · FEAM · LOOP · KBLB · CITR · FEAV · NEU · HDSN · SNES · ODC · RPM

See full Specialty Chemicals rankings →

Which Other Stocks Score Like AMTX on Quality?

Closest companies to AMTX’s Quality of Company score of 4.5/10, across all industries.

Why Do CirclFi’s 2 Models Disagree on AMTX?

Spread

56%

Fair Value Range

$1.90 – $2.96

A 56% spread represents moderate disagreement. The models agree on direction but differ on magnitude.

Most Bullish

PWERM

$2.96 (+58.1%)

Most Bearish

Dynamic NAV

$1.90 (+1.6%)

What Are the Biggest Risks of Buying AMTX Stock?

Weak Fundamentals

QOC 4.5/10 signals below-average quality.

Macro/Sector Risk

Specialty Chemicals headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View AMTX Data Page →

So Is Aemetis, Inc. (AMTX) Worth Buying in 2026?

Aemetis, Inc. at $1.87 is a genuine coin-flip in our framework. The 1–0 bull-bear split across 2 models, +56.5% model spread, and median fair value of $2.43 (+29.9% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 4.5/10 adds additional caution to the mix.

These are quantitative model outputs, not investment recommendations. Aemetis, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About AMTX Stock?

Should I buy AMTX stock right now?

Based on CirclFi's multi-model analysis, 2 of 2 models see upside for AMTX at $1.87. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Aemetis, Inc.?

Key risks include: a below-average Quality Score of 4.5/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Specialty Chemicals companies. Always diversify and consult a financial advisor.

How does AMTX compare to its competitors?

Among Specialty Chemicals peers, AMTX holds a Quality Score of 4.5/10. Comparable companies include CLMT (QOC 4.9), FEAM (QOC 4.4), LOOP (QOC 5.3). The relative ranking helps investors identify whether AMTX offers better fundamental quality than alternatives in the same sector.

Is AMTX a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AMTX's Quality Score of 4.5/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy AMTX at?

CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $1.90 to $2.96. At $1.87, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for AMTX.

View AMTX Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →